Reports
Sale
Constipation Treatment Market Size, Trends, Report, Forecast: By Product Type: Mu-Opioid Receptor Antagonists, Laxative, Chloride Channel-2 Activator, Guanylate Cyclase-C (GC-C) Agonist, Others; By Disease Type; By Prescription Type; By Distribution Channel; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Constipation Treatment Market Outlook
The constipation treatment market size is expected to grow at a CAGR of 6.70% during the forecast period of 2024-2032, likely to be driven by increasing prevalence of chronic idiopathic constipation, along with increase in drug development research activities across major markets.
Constipation Treatment Market Overview
Constipation is one of the most common gastrointestinal conditions with a prevalence of 20% in the general population and 29.6% in children. In the United States, functional constipation (which is a common subtype of the condition) is responsible for 3% to 5% of the pediatric visits. Around 84% of the functionally constipated children suffer from fecal incontinence, whereas more than one-third of children display behavioral issues due to constipation. Around 12% of the global population reports self-defined constipation, out of which, the American and Asia Pacific population suffers twice as much than the European population.
The constipation treatment market demand is primarily driven by a change in the dietary habits of the population. Dietary causes such as insufficient intake of fiber, anatomical causes, neurologic causes, metabolic and endocrine causes, which include hypokalemia, hypercalcemia, hypothyroidism, diabetes mellitus (DM), and diabetes insipidus, are some of the most common physiological etiologies of the condition.
Surge in Drug Approvals to Boost Constipation Treatment Market Growth
As pediatric constipation has a higher incidence rate, there has been high emphasis on offering better therapeutics solutions to address the unmet needs of children. In May 2023, Ironwood Pharmaceuticals, Inc., announced that the FDA approved LINZESS® (linaclotide), their latest once-daily constipation treatment for children aged between 6-17 years. This is the first and only drug to be approved to treat functional constipation in this section of the population. The drug is developed and marketed by AbbVie and Ironwood Pharmaceuticals together. LINZESS also help in alleviating abdominal pain, bloating, discomfort, and pain associated with IBS-C.
Innovative Technical Approaches to Offer Improved Treatments
Factors like the advent of new technologies, increasing convergence of machine, and computer aided techniques in the healthcare ecosystem, along with a better understanding of the physiological mechanisms of the body, are expected to contribute to the rising constipation treatment market share significantly. Treating chronic idiopathic constipation is a key area of attention amongst scientists since the exact causes are still unknown. In June 2023, the U.S. FDA approved a vibrating capsule called Vibrant to manage chronic idiopathic constipation in patients. Programmed with a computer chip, this capsule starts vibrating, after about 15 hours of being swallowed, after it reaches the colon.
Rising Awareness Campaigns and Initiatives to Make Significant Impact
The constipation treatment market size is further impacted by the advent of latest research and development aimed at providing better therapeutic alternatives to the patients. There have been significant initiatives by the government bodies and non-profit organizations to destigmatize the condition in patients. For instance, December 2023 marks as the constipation awareness month, wherein several numerous organizations join to conduct awareness activities and campaigns to educate the masses about constipation complications and preventive measures.
Constipation Treatment Market Segmentation
Market Breakup by Product Type
- Mu-Opioid Receptor Antagonists
- Laxative
- Chloride Channel-2 Activator
- Guanylate Cyclase-C (GC-C) Agonist
- Others
Market Breakup by Disease Type
- Opioid-Induced Constipation
- Chronic Idiopathic Constipation
- Irritable Bowel Syndrome with Constipation
Market Breakup by Prescription Type
- Corticosteroids Prescribed Drugs
- Over-the-Counter Drugs
Market Breakup by Distribution Channel
- Online Pharmacy
- Drug Store and Retail Pharmacy
- Other
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Constipation Treatment Market Regional Analysis
The United States is expected to lead the market owing to increasing constipation treatment market demand. Having a robust healthcare research and development infrastructure plays a pivotal role in market growth. The region is witnessing continuous research on improving patient outcomes. For instance, in June 2023, The American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) published wherein there was an investigation on new therapeutics methods for chronic idiopathic constipation (CIC). As per the studies, magnesium oxide and Senna (which comes from Senna alexandrina herb) can be used as an alternative. 5-HT4 agonists such as prucalopride have also been recommended for cases wherein the usual OTC treatments have not been responded for CIC.
Constipation Treatment Market: Competitor Landscape
In May 2023, Ironwood Pharmaceuticals, Inc., entered a definitive partnership with VectivBio Holding AG, a clinical-stage biopharmaceutical company leading novel and transformational treatments for severe to rare gastrointestinal conditions. This collaboration is worth around USD 1 billion and is expected to bring effective and improved solutions to cater to a wider section of the patients suffering from gastrointestinal issues.
The key features of the constipation treatment market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Takeda Pharmaceutical Company Ltd.
- Ironwood Pharmaceuticals, Inc.
- Salix Pharmaceuticals, Inc.
- Abbott Laboratories
- AstraZeneca Plc
- Cosmo Pharmaceuticals NV
- Sanofi S.A.
- Bayer AG
- Valeant Pharmaceuticals International Inc.
- Pfizer Inc
- Synergy Pharmaceuticals, Inc.
- Janssen Pharmaceutical Company
- Boehringer Ingelheim GmbH
- Ardelyx Inc.
- AbbVie Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Disease Type |
|
| Breakup by Prescription Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Constipation Treatment Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Constipation Treatment Epidemiology Analysis – Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Constipation Treatment Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Constipation Treatment Epidemiology Forecast (2017-2032)
5.3.1 Germany Constipation Treatment Epidemiology Forecast (2017-2032)
5.3.2 France Constipation Treatment Epidemiology Forecast (2017-2032)
5.3.3 Italy Constipation Treatment Epidemiology Forecast (2017-2032)
5.3.4 Spain Constipation Treatment Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Constipation Treatment Epidemiology Forecast (2017-2032)
5.4 Japan Constipation Treatment Epidemiology Forecast (2017-2032)
6 Constipation Treatment Market Overview – 7MM
6.1 Constipation Treatment Market Historical Value (2017-2023)
6.2 Constipation Treatment Market Forecast Value (2024-2032)
7 Constipation Treatment Market Landscape – 7MM
7.1 Constipation Treatment Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Constipation Treatment Product Landscape
7.2.1 Analysis by Product Type
7.2.2 Analysis by Disease Type
8 Constipation Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Constipation Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Constipation Treatment Market Segmentation – 7MM
11.1 Constipation Treatment Market by Product Type
11.1.1 Market Overview
11.1.2 Mu-Opioid Receptor Antagonists
11.1.3 Laxative
11.1.4 Chloride Channel-2 Activator
11.1.5 Guanylate Cyclase-C (GC-C) Agonist
11.1.6 Others
11.2 Constipation Treatment Market by Disease Type
11.2.1 Market Overview
11.2.2 Opioid-Induced Constipation
11.2.3 Chronic Idiopathic Constipation
11.2.4 Irritable Bowel Syndrome with Constipation
11.3 Constipation Treatment Market by Prescription Type
11.3.1 Market Overview
11.3.2 Corticosteroids Prescribed Drugs
11.3.3 Over-the-Counter Drugs
11.4 Constipation Treatment Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Online Pharmacy
11.4.3 Drug Store and Retail Pharmacy
11.4.4 Other
11.5 Constipation Treatment Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Constipation Treatment Market
12.1 Constipation Treatment Market Historical Value (2017-2023)
12.2 Constipation Treatment Market Forecast Value (2024-2032)
12.2.1 Constipation Treatment Market by Product Type
12.2.2 Constipation Treatment Market by Disease Type
13 EU-4 and United Kingdom Constipation Treatment Market
13.1 Constipation Treatment Market Historical Value (2017-2023)
13.2 Constipation Treatment Market Forecast Value (2024-2032)
13.3 Germany Constipation Treatment Market Overview
13.3.1 Constipation Treatment Market by Product Type
13.3.2 Constipation Treatment Market by Disease Type
13.4 France Constipation Treatment Market Overview
13.4.1 Constipation Treatment Market by Product Type
13.4.2 Constipation Treatment Market by Disease Type
13.5 Italy Constipation Treatment Market Overview
13.5.1 Constipation Treatment Market by Product Type
13.5.2 Constipation Treatment Market by Disease Type
13.6 Spain Constipation Treatment Market Overview
13.6.1 Constipation Treatment Market by Product Type
13.6.2 Constipation Treatment Market by Disease Type
13.7 United Kingdom Constipation Treatment Market Overview
13.7.1 Constipation Treatment Market by Product Type
13.7.2 Constipation Treatment Market by Disease Type
14 Japan Constipation Treatment Market
14.1 Constipation Treatment Market Historical Value (2017-2023)
14.2 Constipation Treatment Market Forecast Value (2024-2032)
14.2.1 Constipation Treatment Market by Product Type
14.2.2 Constipation Treatment Market by Disease Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding and Investment Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Takeda Pharmaceutical Company Ltd.
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Ironwood Pharmaceuticals, Inc.
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Salix Pharmaceuticals, Inc.
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Abbott Laboratories
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 AstraZeneca Plc
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Cosmo Pharmaceuticals NV
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Sanofi S.A.
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Bayer AG
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Valeant Pharmaceuticals International Inc.
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Pfizer Inc
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Synergy Pharmaceuticals, Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Janssen Pharmaceutical Company
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Boehringer Ingelheim GmbH
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Ardelyx Inc.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 AbbVie Inc.
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Company Competitiveness Analysis (Additional Insight)
22.1 Very Small Companies
22.2 Small Companies
22.3 Mid-Sized Companies
22.4 Large Companies
22.5 Very Large Companies
23 Payment Methods (Additional Insight)
23.1 Government Funded
23.2 Private Insurance
23.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 6.70% during the forecast period of 2024-2032, driven by a surge in drug development activities and rising incidence of chronic idiopathic constipation across the major markets.
The market demand is driven by the growing shift in the dietary habits of the people, along with increasing emphasis on offering improved and innovative treatment solutions to the patients. The growing prevalence of awareness campaigns and initiatives by both public as well as private institutions to spread relevant information on the condition is another factor.
The expediated drug development and rising number of drug approvals is one of the major market trends. In May 2023, the FDA approved Ironwood Pharmaceutical’s drug LINZESS® (linaclotide) for treating functional constipation in children aged between 6-17 years.
Based on product types, the market is divided into Mu-Opioid receptor antagonists, laxative, chloride channel-2 activator, and guanylate cyclase-C (GC-C) agonist, among others.
Opioid-induced constipation, chronic idiopathic constipation and irritable bowel syndrome with constipation are common disease types among others.
Major distribution channels include online pharmacies, retail pharmacies, and drug stores.
Based on prescription types, it is divided into corticosteroids prescribed drugs and over-the-counter drugs.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Takeda Pharmaceutical Company Ltd., Ironwood Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Abbott Laboratories, AstraZeneca Plc., Cosmo Pharmaceuticals NV, Sanofi S.A., Bayer AG, Valeant Pharmaceuticals International Inc., Pfizer Inc., Synergy Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Ardelyx Inc., AbbVie Inc., and Janssen Pharmaceutical Company.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER